

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/609,147

Confirmation No.: 6705

Filing Date: June 27, 2003

Examiner: Paul V. Ward

Group Art Unit: 1614

Applicants: Knegtel et al.

For: CASPASE INHIBITORS AND USES THEREOF

September 5, 2006
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

Copies of references Citation Nos. B1-B5; C1-C7 are attached.

Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.

A copy of the International Search Report received in the corresponding PCT Application No. _____ is attached herewith.

(b) No fee is believed due because:

The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

The Information Disclosure Statement is being concurrently filed with the above-identified application.

The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./

foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and


Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,


Jennifer G. Che, Reg. No. 58,035

Agent for Applicants

Lisa A. Dixon, Reg. No. 40,995

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-6535

Fax.: (617) 444-6483

Customer No. 27916

I hereby certify that this correspondence and any documents referred to as attached hereto are being deposited with the U.S. Postal Service with sufficient postage as Express Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 5, 2006.

Lisa M. Romano

Signature

ALL REFERENCES CONSIDERED² EXCEPT WHERE LINED THROUGH. /P.W./



Modified Form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | |
|-------------------------------|------------------|
| Application Number | 10/609,147 |
| Filing Date | June 27, 2003 |
| First Named Inventor | Ronald Knegel |
| Group Art Unit | 1614 |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | VPI/02-110 US |

U.S. PATENT DOCUMENTS

| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
|---------------|-------------|--------------------------|-------------------|-------------------------------------|-------|-----------|----------------------------|
| A1 | 5,756,466 | 26-May-1998 | Bemis et al. | | | | |
| A2 | 4,728,647 | 1-Mar-1988 | Benavides, et al. | | | | |
| A3 | 5,656,627 | 12-Aug-1997 | Bemis et al. | | | | |
| A4 | 5,847,135 | 08-Dec-1998 | Bemis et al. | | | | |
| A5 | 5,716,929 | 10-Feb-1998 | Bemis et al. | | | | |
| A6 | 6,103,711 | 15-Aug-2000 | Bemis et al. | | | | |
| A7 | 5,973,111 | 26-Oct-1999 | Bemis et al. | | | | |
| A8 | 6,420,522 | 16-Jul-2002 | Bemis et al. | | | | |
| A9 | 6,025,147 | 15-Feb-2000 | Bemis et al. | | | | |
| A10 | 20030162993 | 28-Aug-2003 | Mortimore et al. | | | | |
| A11 | 20040019017 | 29-Jan-2004 | Mortimore et al. | | | | |

FOREIGN PATENT DOCUMENTS

| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes | No |
|---------------|----------|---------------------------------------|-------------------------------------|---------------------|-----------------|----|
| B1 | WO | 96/40647 A1 | Prototek Inc. | 19-Dec-1996 | | |
| B2 | WO | 98/16502 A1 | Warner-Lambert Company | 23-Apr-1998 | | |
| B3 | WO | 98/16505 A1 | Warner-Lambert Company | 23-Apr-1998 | | |
| B4 | WO | 2000/68188 A1 | Texas Biotechnology Corporation | 16-Nov-2000 | | |
| B5 | WO | 2004/58718 A1 | Vertex Pharmaceuticals Incorporated | 15-July-2004 | | |

OTHER NON PATENT LITERATURE DOCUMENTS

| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
|---------------|-----------------------------|---|
| C1 | Semple, G., et al. | "Pyridone-Based Peptidomimetic Inhibitors of Interleukin-1 β -Converting Enzyme (ICE)," <i>Bioorganic & Medicinal Chem. Letters</i> , 7(10):1337-1342 (1997). |
| C2 | Livingston, D.J. | "In Vitro and In Vivo Studies of Ice Inhibitors," <i>J. of Cell. Biochem.</i> , 64(1):19-26 (1997). |
| C3 | Hussain, M. I., et al. | "Some New 2-Aryloxyethyl-3-alpha-substituted Carboxymethyl-6,8-substituted-4-Quinazolones As Possible Anticonvulsants," <i>Pharmazie</i> , 37(6):408-410 (1982). |
| C4 | Hussain, M., Imtiaz, et al. | "Some Newer Quinazolones as Possible Anticonvulsants," <i>J. Chem. Soc. Pak.</i> 6(4):211-215 (1984). |
| C5 | Canonne, P., et al. | "Synthesis of chiral 3-substituted 2,4(H,3H)-quinazolinodiones," <i>Heterocycles</i> , 36(6):1305-1314 (1993). |
| C6 | Gouilleux, L., et al. | "Solid Phase Synthesis of Chiral 3-substituted Quinazoline-2, 4-diones," <i>Tetrahedron Letters</i> , 37(39):7031-7034 (1996). |
| C7 | Gordeev, M. F., et al. | "A General and Efficient Solid Phase Synthesis of Quinazoline-2, 4-diones," <i>Tetrahedron Letters</i> , 38(10):1729-1732 (1997). |

| | | | |
|--------------------|-------------|-----------------|--------|
| Examiner Signature | /Paul Ward/ | Date Considered | 7/1/08 |
|--------------------|-------------|-----------------|--------|

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications). EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.